New hope for tough AML: drug cocktail targets resistant leukemia

NCT ID NCT04774393

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a combination of oral medications for acute myeloid leukemia (AML) that has returned or not responded to treatment. The drugs include decitabine/cedazuridine, venetoclax, and either ivosidenib or enasidenib. The goal is to see if this combination is safe and effective in controlling the disease. About 84 participants will take part in this early-phase trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Decitabine, cedazuridine, venetoclax, ivosidenib, or enasidenib
What this could lead to: If successful, this could offer a new treatment option for patients with hard-to-treat AML, potentially improving remission rates.
What could go wrong: This is an early-phase trial with a small number of participants, so results may not apply to everyone. The drug combination may cause side effects or not work as expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA RECURRENT ACUTE MYELOID LEUKEMIA REFRACTORY ACUTE MYELOID LEUKEMIA

New hope for tough AML: drug cocktail targets resistant leukemia

Summary

What this could mean

Get notified about this study

Conditions

As listed by the trial registrant

Contacts and locations

Locations

More trials for these conditions